Business
ProAxsis Gains CE Mark for its Respiratory Test
ProAxsis Gains CE Mark for its Respiratory Test.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 2638L NetScientific PLC 30 September 2016 \n\n \n \nNetScientific plc\n(\"NetScientific\" or the \"Company\" or the \"Group\")\n \nProAxsis Gains CE Mark for its Respiratory Test\n- CE Mark allows ProAxsis to begin commercialisation in Europe\n \nLondon, UK - 30 September 2016 - NetScientific plc (\"NetScientific\", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that its portfolio company, ProAxsis, has successfully registered a CE Mark to enable commercialisation of its novel ProteaseTag® Active Neutrophil Elastase Immunoassay. \nCommenting on the news, François R. Martelet, Chairman of ProAxsis and Chief Executive Officer of NetScientific, said: \"We are delighted that ProAxsis has achieved a significant milestone in successfully CE marking its novel ProteaseTag® Active Neutrophil Elastase Immunoassay for chronic respiratory diseases. This will help accelerate its commercialisation in the COPD and Cystic Fibrosis markets. \n \n\"ProAxsis is now able to sell its immunoassay in the 28 member states of the European Union, as well as Switzerland, Turkey, Iceland, Norway and Liechtenstein. Achieving CE Mark for its immunoassay demonstrates the Company's clear commitment to delivering first-class quality products to physicians and their patients who suffer from chronic respiratory diseases.\"\n \nThe full text of the announcement issued by ProAxsis on 29 September 2016 is as follows:\n \n \n \n \nProAxsis gains CE Mark for Active Neutrophil Elastase Immunoassay\nProAxsis Limited (www.proaxsis.com) is pleased to announce that it has successfully registered a CE Mark for its novel ProteaseTag® Active Neutrophil Elastase Immunoassay. Neutrophil elastase is a well-recognised biomarker of lung inflammation and infection in chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis and bronchiectasis. The registration of a CE Mark indicates that the ProteaseTag® Active Neutrophil Elastase Immunoassay complies with EU legislation, and enables the company to commercialise the Immunoassay throughout the European market. \nCommenting on the news, Dr David Ribeiro, CEO of ProAxsis, said: \"This is a very proud day for everyone at ProAxsis, with the succes...